PHOENIX: a study protocol for a pilot randomised controlled trial of pre-emptive pharmacogenomic panel testing in acute care settings with health economic evaluations.

BMJ OpenOct 5, 2026 (epub)
Clinical ResearchMedical Genetics

Stefanie Lip, Pieter Theo Pepler, Alex McConnachie et al.

✦ AI-curated · Sources linked

In 30 seconds

The PHOENIX trial is a pilot randomized controlled trial assessing the impact of pre-emptive pharmacogenomic panel testing on adverse drug reactions (ADRs) and treatment failures in acute care settings. Conducted in NHS Greater Glasgow and Clyde, it aims to recruit 2000-4000 adults prescribed PGx-relevant drugs. The primary outcome is ADR or treatment failure within 3 months, with results expected to inform NHS decision-making.

Key findings

  • The trial will evaluate ADRs and treatment failures within 3 months using a blinded outcome adjudication.
  • Participants will be randomized 1:1 to PGx-guided care or standard care with delayed PGx testing.
  • The primary analysis will utilize intention-to-treat logistic regression adjusted for stratification factors.

Why it matters

Understanding the effectiveness of pharmacogenomic testing in acute care could enhance prescribing practices, reduce adverse drug reactions, and improve patient outcomes, particularly in older, multimorbid populations.

Source

PubMed · PMID 42833716

Published in BMJ Open. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.